Avere Therapeutics has burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking a pipeline with an IL-23 drug from Hansoh Pharmaceutical.
Source: FierceBiotech
You may also like
EC approves Erbitux combination for first‑line...
FDA approves Leqembi Iqlik subcutaneous initiation...
AstraZeneca agrees on $1.5bn deal with Dizal...
Cherry appoints Peter Henshaw as new Managing Director
FDA Issues Proposal to Streamline Registration for...
Cellares and Sonoma Biotherapeutics Agree to Automate...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.